“503B outsourcing facility” appears on GLP-1 storefronts as a quality signal, usually in a sentence that also mentions 503A and treats the two as interchangeable sources. They are not interchangeable, and the difference that matters commercially is not the one usually described. An outsourcing facility is not a better pharmacy. It is a legal status a company chooses to take on, pays an annual fee to keep, files production reports to maintain, and which comes with a bulk-ingredient restriction so narrow that for this drug class it is the tightest constraint in the statute. What each section of the law switches on and off is set out in the article comparing the two categories; this page is about the entity.
It is an election, not a license
The statutory definition is unusually plain about this. An outsourcing facility is a facility at one geographic location or address that is engaged in the compounding of sterile drugs, has elected to register as an outsourcing facility, and complies with all of the requirements of the section. The next sentence is the one people miss: an outsourcing facility is not required to be a licensed pharmacy.[1]
Registration runs on an annual clock. To become one, and then during the period beginning October 1 and ending December 31 of each year after, a facility registers its name, place of business, unique facility identifier and a point of contact email address — and indicates whether it intends to compound a drug on the shortage list during the following calendar year.[1] The agency must then publish each registered facility’s name, its state, whether it compounds from bulk drug substances, and whether that bulk compounding is for sterile or nonsterile drugs.[1] How to read that public table as a buyer is covered in the vetting article.
Two things follow from “elected.” Nobody awards the status, so it certifies no assessment at the moment it is granted. And a company can be a competent sterile compounder and simply not have elected, which means the absence of the label is not a finding about the pharmacy.
What electing costs, and what an unpaid invoice does
The category is funded by the facilities in it. For fiscal year 2026 the rates in effect are an annual establishment fee of $20,726, a qualified small-business establishment fee of $6,829 — set at one third of the reinspection base — and a reinspection fee of $20,486, with no small-business reduction on that last one.[2] The rates published for fiscal year 2027, which take effect on October 1, 2026, are $22,074, $7,142 and $21,427.[3]
Small-business status is not generous. It requires gross annual sales of one million dollars or less in the twelve months ending on April 1 of the preceding fiscal year, and it has to be requested inside a one-month window.[4] For anything operating at commercial scale the establishment fee is a fixed annual cost of doing business in the category, payable whether or not an inspection ever happens.
The fee is also load-bearing in a way that reads like an accounting detail and is not. Among the conditions a compounded drug must meet to qualify for the section 503B exemptions is that it be compounded in an outsourcing facility that has paid all fees owed.[1] An unpaid invoice therefore does not produce a fine sitting beside an otherwise lawful operation; it removes a condition from every product the facility makes while the balance stands.
The obligation that makes the category legible
Registering starts a reporting duty with no equivalent on the other side of the line. Upon initial registration, once during June of each year and once during December, an outsourcing facility must report to the agency every drug it compounded in the previous six months — and for each one, the active ingredient, the source of that active ingredient, the national drug code of the source drug or bulk active ingredient where available, the strength per unit, the dosage form and route of administration, the package description, the number of individual units produced, and the code of the final product if assigned.[1]
That is a complete production record, filed twice a year, naming the ingredient supplier. It is also not public: the statute exempts those reports from the inspection provision that makes registrations available to anyone who asks, unless the Secretary finds the exemption inconsistent with the protection of the public health.[1] So the register of who is in the category is open and the register of what they make is closed, which is a distinction worth holding when a seller cites the category as evidence about a product.
When researchers did get a look at those reports, the result complicated the category’s own origin story. A comparison of every current and resolved federal drug shortage through January 27, 2020 against the 503B product reports filed from July 2018 through June 2019 found 344 unique active ingredients on the shortage list and 774 on the product reports — and only 27% of unique ingredients, 74 of 272, on both. 18%, 50 of 272, were compounded in the same dosage form as the product that was short.[5] The category built to cover shortages was mostly making something else.
The bulk list is five substances long
Here is the constraint that decides what an outsourcing facility can actually supply. It may not compound a drug product using a bulk drug substance unless that substance appears on a list identifying bulk drug substances for which there is a clinical need, or the drug compounded from it is on the shortage list at the time of compounding, distribution and dispensing.[1] Building that clinical-need list is a formal process: a Federal Register notice proposing substances with the rationale for each, a comment period of not less than 60 calendar days, then a notice designating what goes on.[1]
More than a decade after the statute passed, the list has five entries. Diphenylcyclopropenone, for topical use only. Glycolic acid, for topical use in concentrations up to 70%. Quinacrine hydrochloride, for oral use only. Squaric acid dibutyl ester, for topical use only. Trichloroacetic acid, for topical use only. Not one is injectable. A second table on the same page lists 22 substances the agency evaluated and determined there is not a clinical need for, and the most recent addition to the included list was published in April 2023.[6]
Neither semaglutide nor tirzepatide appears on either table — not as included, not as refused. The only door that ever opened for them was the shortage listing, and what happened to that is the subject of the shortage article. The category everyone cites as the more capable one is, on its own bulk pathway, the narrowest route in the statute.
Most bulk compounding runs on enforcement discretion
A five-substance list cannot support an industry, and the agency knows it. An interim policy sorts substances nominated by the public into three categories. Category 1 substances may be eligible for the list, were nominated with sufficient information to evaluate, and appear on no other list — and the agency does not intend to take action against an outsourcing facility for compounding with them where the conditions in the guidance are met. Category 2 substances carry safety risks the agency has identified pending further evaluation. Category 3 substances were nominated with insufficient information to evaluate at all.[7]
Category 1 is therefore not a permission. It is a published intention not to enforce, which is a different legal object and can be revised. And the route into it has closed: the guidance states that the agency does not intend to place bulk drug substances nominated on or after January 7, 2025 into these categories.[7] A facility considering a new bulk ingredient today has the five-substance list, the shortage list, and nothing else.
What the register says about the industry
The published table of registered facilities, updated September 8, 2026, describes a small and fast-turning industry rather than an established one. It carries 96 facilities spread across 28 jurisdictions, and two states hold a third of them: 17 in Texas and 15 in Florida. 39 of the 96 — 41% — first registered in 2024 or later, and only 2 date back to 2013, the year the statute was enacted.[8]
One column deserves its own sentence. 90 of the 96 told the agency they intend to compound sterile drugs from bulk drug substances, and the agency’s own footnote states that the information in that column was provided by the facility at registration and has not been verified.[8] A declared intention is the kind of fact that looks like a finding in a table and is not one.
How this market actually cites the category
Across the 286 sellers written up here, 65 state a compounding category at all and 22 mention 503B. Of those 22, only 2 name 503B without also naming 503A; the other 20 present the pair as an undifferentiated source, in the form “503A and 503B pharmacies,” usually without naming any of them. Two sellers use the phrase “503A Outsourcing Facilities,” which fuses the name of one category to the name of the other, and one describes its pharmacies as 503A on one page and 503B on another.
None of that establishes anything about product quality, and none of it is evidence of intent — these are ordinary marketing pages written by people who are not lawyers. It does establish that the category is being cited as a reassurance rather than as a specific claim, which is the opposite of how it functions in the statute, where it is a set of conditions a particular facility either meets or does not. What each company publishes is recorded in the individual seller write-ups.
What this does not establish
Nothing here says a 503B product is safer than a 503A one. No comparative outcome data exists, and what the agency describes is a difference in obligations rather than in results. Nothing here identifies any seller as misleading, and the roster counts are floors from what each company publishes on the pages examined rather than a census of the market.
The conclusion is narrow and it is about the word. Electing into the category buys federal registration, a fee bill, an inspection schedule and a twice-yearly production report, and it buys a bulk-ingredient pathway that for these two molecules is closed. It does not change the status of what comes out: compounded drugs are not FDA-approved, and the agency does not verify the safety, effectiveness or quality of compounded drugs before they are marketed.[9] What that phrase carries is set out in the approval article, and how a category claim is weighed here is in the methodology.